Related Experiment Video

Updated: Jun 5, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Sirolimus and its analogs and its effects on vascular diseases

Steven J Adelman1

  • 1Vascular Strategies LLC 100 Lancaster Ave Wynnewood, PA 19096, USA. sadelman@vascularstrategy.com

Current Pharmaceutical Design
|January 7, 2011
PubMed

Insights

Sirolimus (rapamycin) inhibits the target of rapamycin (TOR) pathway, crucial for cell function. This review explores its use in cardiovascular diseases like restenosis and atherosclerosis, including drug-eluting stents and targeted delivery.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Molecular Biology

Background:

  • The target of rapamycin (TOR) pathway is fundamental to cell proliferation and immune response.
  • TOR signaling is implicated in various human disorders, including cardiovascular diseases such as atherosclerosis and restenosis.
  • Sirolimus (rapamycin) is an FDA-approved immunosuppressant that inhibits TOR.

Purpose of the Study:

  • To review the current therapeutic applications of Sirolimus and TOR inhibitors in cardiovascular disorders.
  • To discuss the rationale, successes, and future directions for using TOR inhibition in managing cardiovascular diseases.
  • To explore strategies for targeted delivery of TOR inhibitors to mitigate systemic toxicities.

Main Methods:

  • Review of existing literature on Sirolimus, TOR pathway, and cardiovascular diseases.
  • Analysis of clinical data from drug-eluting stents for restenosis treatment.
  • Examination of preclinical studies investigating TOR inhibition in atherosclerosis models.

Main Results:

  • Sirolimus-eluting stents have demonstrated success in locally treating restenosis post-percutaneous coronary intervention.
  • Preclinical studies suggest a role for TOR inhibition in managing atherosclerosis.
  • Targeted delivery approaches are being developed to improve safety and efficacy.

Conclusions:

  • TOR inhibition represents a promising therapeutic strategy for cardiovascular diseases.
  • Local delivery of Sirolimus via drug-eluting stents is effective for restenosis.
  • Further research into targeted delivery systems is warranted for broader cardiovascular applications.

More Related Videos

Rodent Inferior Vena Cava Venoplasty Balloon Model05:44

Rodent Inferior Vena Cava Venoplasty Balloon Model

Published on: May 24, 2024

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...